Q2 Earnings Forecast for Adicet Bio Issued By HC Wainwright

Adicet Bio, Inc. (NASDAQ:ACET - Free Report) - Research analysts at HC Wainwright issued their Q2 2025 earnings estimates for shares of Adicet Bio in a research report issued on Wednesday, July 23rd. HC Wainwright analyst R. Burns anticipates that the company will earn ($0.32) per share for the quarter. HC Wainwright has a "Buy" rating and a $4.00 price objective on the stock. The consensus estimate for Adicet Bio's current full-year earnings is ($1.39) per share. HC Wainwright also issued estimates for Adicet Bio's Q3 2025 earnings at ($0.32) EPS, Q4 2025 earnings at ($0.30) EPS, FY2025 earnings at ($1.25) EPS, Q3 2026 earnings at ($0.30) EPS, Q4 2026 earnings at ($0.31) EPS and FY2026 earnings at ($1.18) EPS.

Adicet Bio (NASDAQ:ACET - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported ($0.31) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.03.

Separately, Wall Street Zen initiated coverage on shares of Adicet Bio in a research report on Friday, May 16th. They issued a "hold" rating on the stock. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, Adicet Bio has a consensus rating of "Moderate Buy" and a consensus price target of $6.00.

Adicet Bio Stock Performance

Shares of NASDAQ ACET traded down $0.00 during trading hours on Friday, hitting $0.77. 122,175 shares of the stock were exchanged, compared to its average volume of 380,294. Adicet Bio has a 1-year low of $0.45 and a 1-year high of $1.70. The company has a market cap of $63.81 million, a PE ratio of -0.59 and a beta of 1.62. The company's fifty day simple moving average is $0.71 and its two-hundred day simple moving average is $0.76.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in ACET. Vontobel Holding Ltd. boosted its stake in Adicet Bio by 33.3% in the second quarter. Vontobel Holding Ltd. now owns 80,000 shares of the company's stock valued at $49,000 after acquiring an additional 20,000 shares during the last quarter. Northern Trust Corp boosted its position in Adicet Bio by 25.1% during the 4th quarter. Northern Trust Corp now owns 140,369 shares of the company's stock valued at $135,000 after buying an additional 28,153 shares during the period. Virtu Financial LLC bought a new position in Adicet Bio in the 4th quarter worth $29,000. Acadian Asset Management LLC raised its holdings in Adicet Bio by 1.8% in the 1st quarter. Acadian Asset Management LLC now owns 2,039,324 shares of the company's stock worth $1,538,000 after purchasing an additional 36,277 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its stake in shares of Adicet Bio by 1.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 3,816,556 shares of the company's stock worth $2,882,000 after acquiring an additional 63,691 shares in the last quarter. 83.89% of the stock is currently owned by institutional investors and hedge funds.

Adicet Bio Company Profile

Adicet Bio, Inc, a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.